Please assess the completion status of the following clinical trial:

Trial Title: Impedancemetry in Patients Monitored for Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 years and under 80 years~* Patients who have been diagnosed with PAH (group 1 PH according to the Nice 2013 classification) or post-embolic pulmonary hypertension (group 4 PH) under medical treatment;~* HTP incident or prevalent less than 6 months~* Patient coming for follow-up or emergency consultation or hospitalization with a clinical examination and a walking test~* Patient affiliated to a health insurance scheme~* Patient having signed informed consent~Exclusion Criteria:~* Subjects under juridical protections or tutelage measure~* pregnant or lactating woman~* pulmonary hypertension du to cardiac pathology, chronic respiratory disease, or uncertain determinism.~* pulmonary hypertension of group 4 treated surgically or endoscopically.~* pulmonary hypertension incident or prevail for 6 months or more~* contraindication to impedancemetry~* inability to perform a walking test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- cardiac impedancemetry (Type: EXPERIMENTAL): Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for PH. Patients are included via the competence center of the PHP of the Midi Pyrenees region. The cardiac output is measured by impedance measurement at rest and during the walking test. The NO / CO coupled transfer measurement is performed at rest. The physician performing the consultation will not know the results of the IPC and these results will not influence the subsequent management.~The patient will be followed for 18 months as part of the research.

Based on this trial design, predict the completion outcome and termination type (if applicable).